Obsidian Therapeutics, Inc.
Model cytoTIL15 -Cell and Gene Therapy
Engineered with membrane-bound IL15, Eliminates toxic IL2 regimen, increasing patient accessibility to TIL therapy, Drives improved persistence, IL15 expression controlled by acetazolamide (ACZ), via cytoDRiVE® technology.
